Alzheimer's disease (AD) is a heterogeneous neurodegenerative disorder that may be caused by epigenetic and/or genetic factors. For example, the epsilon allele encoded by the apolipoprotein E (APOE) gene on chromosome 19 increases the risk of sporadic AD, while head trauma is an environment risk factor for sporadic AD. Further familial, AD (FAD) is caused by autosomal dominant mutations in the amyloid precursor protein (APP) gene on chromosomal 21, as well as in genes encoding two different membrane spanning proteins known as Presenilin 1 (PS-1) and Presenilin 2 (PS-2) on chromosome 14 and 1, respectively, while trisomy 21 (Down's syndrome) patients developed extensive AD-like pathology by age 40. However, other AD genes and epigenetic risk factors undoubtedly exist. Despite the genotypic and phenotypic heterogeneity of AD, elderly patients with a progressive dementia are assigned a diagnosis of AD when postmortem examination reveals numerous telencephalic Abeta-rich senile plaques (SPs) and tau-rich neurofibrillary tangles (NFTs). Thus, we hypothesize that SPs and NFTs represent part of a final common pathway leading to neuron loss and dementia in AD, and that head trauma augments this process. Indeed, head trauma could increase the risk for AD by acting synergistically (i.e. as a """"""""second hit"""""""" with AD pathologies. Since animal models that recapitulate AD-like SPs and NFTs enable rigorous tests of the hypothesis, the Aims of Project 4 are designed to accomplish this goal by: 1) Inducing or augmenting the formation of AD-like SPs in existing transgenic mice that over-express mutant human APP and develop age-related SP-like lesions by subjecting young and aged mice to traumatic brain injury (TBI); 2) Developing transgenic mice that over-express human tau and accumulate tau in neuronal perikarya; 3) Cross-breeding human tau transgenic mice with mutant human APP transgenic mice described above in Aim 1; 4) Inducing or augmenting the formation of AD-like SPs, perikaryal tau accumulations and NFTs in the tau and crossed transgenic mice described above in Aim 3 by subjecting young and aged mice to TBI; 5) Determining modes of neuron degeneration in regions of the brain with and without AD-like SPs, perikaryal tau accumulations and NFTs before and after TBI or sham treatment of the transgenic mice described in Aims 1-3 using biochemical, morphological and """"""""single cell mRNA profiling"""""""" methods.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG011542-07
Application #
6201020
Study Section
Project Start
1999-09-01
Project End
2000-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Brunden, Kurt R; Ballatore, Carlo; Lee, Virginia M-Y et al. (2012) Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 40:661-6
Hurtado, David E; Molina-Porcel, Laura; Carroll, Jenna C et al. (2012) Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J Neurosci 32:7392-402
Xu, Shaohua; Brunden, Kurt R; Trojanowski, John Q et al. (2010) Characterization of tau fibrillization in vitro. Alzheimers Dement 6:110-7
Brunden, Kurt R; Ballatore, Carlo; Crowe, Alex et al. (2010) Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 223:304-10
Hurtado, David E; Molina-Porcel, Laura; Iba, Michiyo et al. (2010) A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol 177:1977-88
Crowe, Alex; Huang, Wenwei; Ballatore, Carlo et al. (2009) Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48:7732-45
Chen, Xiao-Han; Johnson, Victoria E; Uryu, Kunihiro et al. (2009) A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol 19:214-23
Brunden, Kurt R; Trojanowski, John Q; Lee, Virginia M-Y (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8:783-93
Shineman, Diana W; Dain, Aleksandra S; Kim, Minkyu L et al. (2009) Constitutively active Akt inhibits trafficking of amyloid precursor protein and amyloid precursor protein metabolites through feedback inhibition of phosphoinositide 3-kinase. Biochemistry 48:3787-94
Kim, Minkyu L; Zhang, Bin; Mills, Ian P et al. (2008) Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. J Neurosci 28:12052-61

Showing the most recent 10 out of 94 publications